Cancer and Hematology Centers of Western Michigan (CHC)’s Yuanbin Chen, MD, PhD, recently co-authored another publication published in the esteemed medical journal The Lancet. The article details findings from CHC’s CASPIAN trial, which studied the use of durvalumab plus platinum–etoposide as first-line therapy in patients with small cell lung cancer. To read the article, click here.
CHC is proud of Dr. Chen’s hard work and dedication to research. Our centers also participate in all phases of clinical trials for cancer patients, and we are involved in many Phase I trials with our START Midwest program, part of the world’s largest Phase I clinical trial network.